查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1876156

核酸内切酶市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察与预测（2024-2032 年）

Endonucleases Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

核酸内切酶市场成长驱动因子

全球核酸内切酶市场正经历强劲成长，主要得益于基因组研究、基因编辑技术和个人化医疗的快速发展。根据 Fortune Business Insights 预测，该市场规模预计将在 2024 年达到 3.571 亿美元，并在 2025 年达到 3.903 亿美元。预计到 2032 年，该市场规模将进一步成长至 7.286 亿美元，在预测期（2025-2032 年）内，复合年增长率 (CAGR) 为 9.32%。北美预计将在 2024 年以 47.61% 的市场占有率引领市场，这主要得益于其高额的研发投入、先进的生物技术基础设施以及 Thermo Fisher Scientific、Takara Bio 和 New England BioLabs 等主要企业的强大影响力。

内切酶，又称为“分子剪刀”，是重要的酶，能够在DNA内部特定位点进行切割。它们是基因工程、重组DNA技术、诊断和治疗研发中不可或缺的工具，构成了现代分子生物学和基因组编辑的基础。市场成长主要受CRISPR应用、合成生物学和精准基因组学领域研发投入的增加以及基因治疗临床管线的不断扩展所驱动。

市场动态

科技创新驱动研究活动

CRISPR-Cas基因编辑系统的兴起彻底改变了分子生物学和生物技术。截至2025年初，已有超过150项临床试验正在探索基因编辑疗法，推动了对精准内切酶的需求激增。更高的精准度和更低的脱靶效应使得CRISPR及类似核酸酶成为药物研发和治疗应用的关键工具。像 CRISPR Therapeutics 这样的公司正在积极开发基于 CRISPR/Cas9 的疗法，例如 CTX112，用于治疗 CD19 阳性恶性肿瘤和自体免疫疾病，展现出巨大的商业潜力。

监理与伦理挑战制约市场成长

关于人类基因组编辑的严格监管和伦理问题仍然是市场扩张的重大挑战。诸如中国备受争议的 "CRISPR 婴儿" 事件等事件引发了全球关注，加强了审批框架，并延缓了商业化进程。这些监管措施增加了生技公司的营运复杂性，并延长了产品开发週期。

个人化医疗与精准基因体学的机会

全球对个人化医疗的日益关注正在为核酸内切酶市场创造丰厚的机会。核酸内切酶能够实现精确的 DNA 修饰，从而支持客製化治疗方案设计和基于基因的诊断。製药公司与基因组学研究机构之间的合作正在加速这一转变。例如，CRISPR Therapeutics 和 Vertex Pharmaceuticals 正在扩大合作，共同开发下一代基因疗法，进一步将核酸内切酶整合到先进的医疗应用中。

转型为基于 CRISPR 的诊断技术

诊断领域正迅速转向利用 CRISPR 技术的检测系统，例如 DETECTR 和 SHERLOCK。与 PCR 相比，这些技术具有更高的灵敏度、更快的检测速度和更低的成本。利用 Cas12 和 Cas13 内切酶的 CRISPR 检测方法目前用于即时病原体检测、传染病筛检和精准诊断，在更广泛的内切酶生态系统中开闢了一个高成长的区隔市场。

区隔市场洞察

依类型：

2024 年，特定内切酶区隔市场引领市场，这主要得益于它们在 CRISPR-Cas 和限制性内切酶技术中的重要作用。在这个区隔市场中，限制性内切酶和 CRISPR 核酸酶的需求量最大，尤其是在基因编辑研究领域。 GMP 级 Cas9 和 Cas12 酶现已成为细胞和基因治疗生产中的标准组件。

依应用：

2024 年，基因组学和基因工程领域引领市场，这主要得益于它们在研究实验室和临床试验中日益增长的应用。根据美国细胞与基因治疗学会 (ASCTH) 的报告，到 2024 年，全球将有超过 4000 种基因、细胞和 RNA 疗法正在研发中，这凸显了核酸内切酶在基因组工程和验证中的广泛应用。预计研发领域将显着成长，这主要得益于核酸酶在标靶验证和生物标记鑑定中日益广泛的应用。

资料来源：

到 2024 年，原核核酸内切酶将占市场主导地位，占酵素供应的大部分。其在合成生物学、克隆和分子诊断领域的广泛应用正在推动该区隔市场的扩张。 Thermo Fisher Scientific 和 New England Biolabs 等公司提供全面的原核酶产品线，为大规模的学术和工业研究提供支援。

依最终使用者划分：

到 2024 年，製药和生技公司将占最大的市场占有率，这反映出生物製剂生产、基因编辑和治疗药物研发领域对核酸酶的需求不断增长。 Intellia Therapeutics 和 CRISPR Therapeutics 等领先公司正在利用 Cas9 核酸酶作为其药物发现流程的关键组成部分。同时，在政府和私人研究经费不断增加的支持下，学术研究领域也稳定成长。

区域展望

北美：

北美引领全球市场，预计到 2024 年将达到 1.7 亿美元，这得益于其完善的生物技术基础设施和对基因组学研究的大量投入。美国是基于 CRISPR 技术的创新和治疗开发的重要中心，例如安捷伦科技公司在 2023 年投资 7.25 亿美元，用于扩大其在科罗拉多州的核酸生产能力。

欧洲：

欧洲在 2024 年占第二大市场占有率，预计到 2032 年将保持稳定成长。德国、瑞士和英国的创新集群正在推动基因组医学的应用。欧盟精准医疗计画的资金持续推动着区域市场的成长。

亚太地区：

亚太地区占第三大市场占有率，预计到 2032 年将实现最高的复合年增长率。中国、日本和印度等国家正在农业生物技术、临床基因组学和诊断领域快速采用基因编辑工具。政府的策略支援和新兴生物技术新创企业的涌现正在加速区域市场的渗透。

拉丁美洲与中东及非洲：

在生物技术研究投资增加和与国际製药公司合作扩大的支持下，这些地区预计将经历缓慢但稳定的成长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场推动因素
  • 市场阻碍因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • DNA修饰技术进展
  • 基因工程技术进展
  • 主要公司新产品发布
  • 主要产业趋势，包括併购和合作
  • 概述：基于CRISPR疗法的关键新创公司

第五章：全球核酸内切酶市场分析、洞察与预测 (2019-2032)

  • 依类型划分的市场分析、洞察与预测
    • 特异性核酸内切酶
      • 限制性内切酶
      • CRISPR-Cas 核酸酶
      • 其他
    • 非特异性核酸内切酶
      • DNA酶
      • RN酶
      • 其他
  • 依应用划分的市场分析、洞察与预测
    • 基因体学与基因工程
    • 药物发现与研究
    • 分子生物学
    • 其他
  • 依应用划分的市场分析、洞察与预测来源
    • 原核生物
    • 真核生物
    • 其他
  • 市场分析、洞察与预测 - 依最终用户划分
    • 製药和生技公司
    • 学术和研究机构
    • 其他
  • 市场分析、洞察与预测 - 依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美内切酶市场分析、洞察与预测，2019-2032

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲内切酶市场分析， 2019-2032 年内切酶市场分析、洞察与预测

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区内切酶市场分析、洞察与预测，2019-2032

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲内切酶市场分析、洞察与预测，2019-2032

  • 依国家/地区
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东和非洲内切酶市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 海湾合作委员会 (GCC)
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2024）
  • 公司简介
  • New England Biolabs
  • Promega Corporation
  • Thermo Fisher Scientific Inc.
  • Takara Bio Inc.
  • QIAGEN
  • Agilent Technologies Inc.
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd
Product Code: FBI113905

Growth Factors of endonucleases Market

The global endonucleases market is demonstrating robust growth, fueled by accelerating advances in genomic research, gene-editing technologies, and personalized medicine. According to Fortune Business Insights, the market was valued at USD 357.1 million in 2024, is projected to reach USD 390.3 million in 2025, and is expected to rise significantly to USD 728.6 million by 2032, growing at a CAGR of 9.32% during the forecast period (2025-2032). North America led the market with a 47.61% share in 2024, supported by high R&D investments, advanced biotechnology infrastructure, and the strong presence of major players such as Thermo Fisher Scientific Inc., Takara Bio Inc., and New England Biolabs.

Endonucleases, often referred to as "molecular scissors," are crucial enzymes that cut DNA internally at specific sites. They are essential tools in genetic engineering, recombinant DNA technology, diagnostics, and therapeutic development, forming the foundation of modern molecular biology and genome editing. The market's growth is primarily driven by increasing research activity in CRISPR-based applications, synthetic biology, and precision genomics, alongside expanding clinical pipelines for gene therapies.

Market Dynamics

Technological Innovations Propel Research Activities

The rise of CRISPR-Cas gene-editing systems has revolutionized molecular biology and biotechnology. With over 150 active clinical trials exploring gene-editing therapies as of early 2025, demand for high-fidelity endonucleases has surged. Enhanced accuracy and reduced off-target effects have made CRISPR and similar nucleases indispensable in drug development and therapeutic applications. Companies like CRISPR Therapeutics are actively developing CRISPR/Cas9-based therapies, such as CTX112 for treating CD19+ malignancies and autoimmune diseases, signaling strong commercial potential.

Regulatory and Ethical Challenges Restrain Market Growth

Stringent regulations and ethical concerns regarding human genome modification remain significant challenges for market expansion. Events such as the controversial "CRISPR babies" case in China have led to global scrutiny, triggering tighter approval frameworks and delayed commercialization. These restrictions increase operational complexity for biotech firms and extend product development timelines.

Opportunities in Personalized Medicine and Precision Genomics

The growing global focus on personalized medicine is creating lucrative opportunities for the endonucleases market. By enabling precise DNA modification, endonucleases support customized therapeutic design and gene-based diagnostics. Collaborations between pharmaceutical companies and genomic research institutions are accelerating this transition. For example, CRISPR Therapeutics and Vertex Pharmaceuticals are expanding partnerships to develop next-generation gene therapies, reinforcing the integration of endonucleases into advanced medical applications.

Shift Toward CRISPR-based Diagnostics

The diagnostics landscape is shifting rapidly toward CRISPR-enabled detection systems, such as DETECTR and SHERLOCK. These technologies offer high sensitivity, faster results, and lower costs compared to PCR. CRISPR-based assays leveraging Cas12 and Cas13 endonucleases are now utilized for real-time pathogen detection, infectious disease screening, and precision diagnostics-creating a high-growth niche within the broader endonuclease ecosystem.

Segmentation Insights

By Type:

The specific endonucleases segment dominated the market in 2024, driven by their critical role in CRISPR-Cas and restriction enzyme technologies. Within this segment, restriction enzymes and CRISPR nucleases accounted for the largest demand, particularly in gene-editing research. Cas9 and Cas12 enzymes, available in GMP-grade forms, are now standard components in cell and gene therapy manufacturing.

By Application:

The genomics and genetic engineering segment led the market in 2024 due to growing adoption in research laboratories and clinical trials. The American Society of Cell & Gene Therapy reported that more than 4,000 gene, cell, and RNA therapies were in development globally as of 2024, highlighting the extensive utilization of endonucleases in genome manipulation and validation. The drug discovery and research segment is expected to show significant growth, driven by increasing use of nucleases in target validation and biomarker identification.

By Source:

In 2024, prokaryotic-derived endonucleases dominated the market, accounting for the majority of enzyme supply. Their broad application in synthetic biology, cloning, and molecular diagnostics has fueled segment expansion. Companies like Thermo Fisher Scientific Inc. and New England Biolabs offer comprehensive prokaryotic enzyme product lines that support large-scale academic and industrial research.

By End User:

Pharmaceutical and biotechnology companies held the largest market share in 2024, reflecting growing demand for nucleases in biologics production, gene editing, and therapeutic pipeline development. Major players such as Intellia Therapeutics and CRISPR Therapeutics utilize Cas9 nucleases as key components in drug discovery workflows. Meanwhile, academic and research institutes represent a steadily growing segment, supported by increasing government and private research funding.

Regional Outlook

North America:

North America dominated the global market in 2024, valued at USD 170.0 million, owing to its established biotechnology infrastructure and extensive funding for genomics research. The U.S. remains the primary hub for CRISPR-based innovation and therapeutic development, with companies like Agilent Technologies Inc. investing USD 725 million in 2023 to expand nucleic acid manufacturing capacity in Colorado.

Europe:

Europe accounted for the second-largest market share in 2024 and is projected to maintain steady growth through 2032. Innovation clusters in Germany, Switzerland, and the U.K. are leading genomic medicine adoption. The European Union's funding for precision medicine initiatives continues to boost the regional market.

Asia Pacific:

Asia Pacific ranks third in market share but is expected to record the fastest CAGR through 2032. Countries like China, Japan, and India are witnessing rapid adoption of gene-editing tools for agricultural biotechnology, clinical genomics, and diagnostics. Strategic government support and emerging biotech startups are accelerating regional market penetration.

Latin America and Middle East & Africa:

These regions are projected to experience moderate but consistent growth, supported by rising biotechnology research investments and expanding partnerships with international pharmaceutical firms.

Competitive Landscape and Key Developments

The market is semi-fragmented, featuring both established players and emerging biotech firms. Major companies-including Takara Bio Inc., Thermo Fisher Scientific Inc., and New England Biolabs-maintain dominance through broad product portfolios, strong academic partnerships, and extensive distribution networks. New entrants are focusing on CRISPR-based innovations, enzyme optimization, and regional market expansion.

Key Developments:

  • July 2025: New England Biolabs launched Monarch DNase I (lyophilized), optimized for removing genomic DNA contamination in RNA samples.
  • May 2025: Biomay AG introduced an FDA-grade CRISPR/Cas9 nuclease for genome-editing applications.
  • January 2023: Aldevron LLC launched Eureca-V Nuclease for diagnostic, therapeutic, and agricultural workflows.
  • January 2020: ERS Genomics Limited partnered with New England Biolabs to commercialize CRISPR-based tools and reagents.

Conclusion

The global endonucleases market is poised for substantial expansion from USD 390.3 million in 2025 to USD 728.6 million by 2032, driven by rapid progress in CRISPR gene editing, synthetic biology, and personalized medicine. North America will continue to dominate, while Asia Pacific emerges as the fastest-growing region. With ongoing advancements in enzyme engineering, therapeutic development, and precision diagnostics, endonucleases are set to remain a cornerstone of the global biotechnology revolution.

Segmentation By Type

  • Specific Endonucleases
    • Restriction Enzymes
    • CRISPR-Cas Nucleases
    • Others
  • Non-specific Endonucleases
    • DNases
    • RNases
    • Others

By Application

  • Genomics & Genetic Engineering
  • Drug Discovery & Research
  • Molecular Biology
  • Others

By Source

  • Prokaryotic
  • Eukaryotic
  • Others

By End User

  • Pharmaceutical and Biotechnology Companies
  • Academic & Research Institutes
  • Others

By Geography

  • North America (By Type, Application, Source, End User, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Application, Source, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Application, Source, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Application, Source, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Application, Source, End User, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Technological Advancements in DNA Modification Techniques
  • 4.2. Technological Advancements in Genetic Engineering
  • 4.3. New Product Launches, By Key Players
  • 4.4. Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
  • 4.5. Overview: Key Start-ups in CRISPR-based Therapeutics

5. Global Endonucleases Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Specific Endonucleases
      • 5.1.1.1. Restriction enzymes
      • 5.1.1.2. CRISPR-Cas nucleases
      • 5.1.1.3. Others
    • 5.1.2. Non-specific Endonucleases
      • 5.1.2.1. DNases
      • 5.1.2.2. RNases
      • 5.1.2.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Genomics & Genetic Engineering
    • 5.2.2. Drug Discovery & Research
    • 5.2.3. Molecular Biology
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Source
    • 5.3.1. Prokaryotic
    • 5.3.2. Eukaryotic
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Pharmaceutical and Biotechnology Companies
    • 5.4.2. Academic & Research Institutes
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Endonucleases Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Specific Endonucleases
      • 6.1.1.1. Restriction enzymes
      • 6.1.1.2. CRISPR-Cas nucleases
      • 6.1.1.3. Others
    • 6.1.2. Non-specific Endonucleases
      • 6.1.2.1. DNases
      • 6.1.2.2. RNases
      • 6.1.2.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Genomics & Genetic Engineering
    • 6.2.2. Drug Discovery & Research
    • 6.2.3. Molecular Biology
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Source
    • 6.3.1. Prokaryotic
    • 6.3.2. Eukaryotic
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By End User
    • 6.4.1. Pharmaceutical and Biotechnology Companies
    • 6.4.2. Academic & Research Institutes
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Endonucleases Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Specific Endonucleases
      • 7.1.1.1. Restriction enzymes
      • 7.1.1.2. CRISPR-Cas nucleases
      • 7.1.1.3. Others
    • 7.1.2. Non-specific Endonucleases
      • 7.1.2.1. DNases
      • 7.1.2.2. RNases
      • 7.1.2.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Genomics & Genetic Engineering
    • 7.2.2. Drug Discovery & Research
    • 7.2.3. Molecular Biology
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Source
    • 7.3.1. Prokaryotic
    • 7.3.2. Eukaryotic
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By End User
    • 7.4.1. Pharmaceutical and Biotechnology Companies
    • 7.4.2. Academic & Research Institutes
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Endonucleases Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Specific Endonucleases
      • 8.1.1.1. Restriction enzymes
      • 8.1.1.2. CRISPR-Cas nucleases
      • 8.1.1.3. Others
    • 8.1.2. Non-specific Endonucleases
      • 8.1.2.1. DNases
      • 8.1.2.2. RNases
      • 8.1.2.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Genomics & Genetic Engineering
    • 8.2.2. Drug Discovery & Research
    • 8.2.3. Molecular Biology
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Source
    • 8.3.1. Prokaryotic
    • 8.3.2. Eukaryotic
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By End User
    • 8.4.1. Pharmaceutical and Biotechnology Companies
    • 8.4.2. Academic & Research Institutes
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Endonucleases Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Specific Endonucleases
      • 9.1.1.1. Restriction enzymes
      • 9.1.1.2. CRISPR-Cas nucleases
      • 9.1.1.3. Others
    • 9.1.2. Non-specific Endonucleases
      • 9.1.2.1. DNases
      • 9.1.2.2. RNases
      • 9.1.2.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Genomics & Genetic Engineering
    • 9.2.2. Drug Discovery & Research
    • 9.2.3. Molecular Biology
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Source
    • 9.3.1. Prokaryotic
    • 9.3.2. Eukaryotic
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By End User
    • 9.4.1. Pharmaceutical and Biotechnology Companies
    • 9.4.2. Academic & Research Institutes
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Endonucleases Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Specific Endonucleases
      • 10.1.1.1. Restriction enzymes
      • 10.1.1.2. CRISPR-Cas nucleases
      • 10.1.1.3. Others
    • 10.1.2. Non-specific Endonucleases
      • 10.1.2.1. DNases
      • 10.1.2.2. RNases
      • 10.1.2.3. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Genomics & Genetic Engineering
    • 10.2.2. Drug Discovery & Research
    • 10.2.3. Molecular Biology
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Source
    • 10.3.1. Prokaryotic
    • 10.3.2. Eukaryotic
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By End User
    • 10.4.1. Pharmaceutical and Biotechnology Companies
    • 10.4.2. Academic & Research Institutes
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 11.2.1. New England Biolabs
    • 11.2.2. Promega Corporation
    • 11.2.3. Thermo Fisher Scientific Inc.
    • 11.2.4. Takara Bio Inc.
    • 11.2.5. QIAGEN
    • 11.2.6. Agilent Technologies Inc.
    • 11.2.7. Merck KGaA
    • 11.2.8. F. Hoffmann-La Roche Ltd

List of Tables

  • Table 1: Global Endonucleases Market Revenue (USD million) Forecast, by Type, 2019-2032
  • Table 2: Global Endonucleases Market Revenue (USD million) Forecast, by Specific Endonucleases, 2019-2032
  • Table 3: Global Endonucleases Market Revenue (USD million) Forecast, by Non-specific Endonucleases, 2019-2032
  • Table 4: Global Endonucleases Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 5: Global Endonucleases Market Revenue (USD million) Forecast, by Source, 2019-2032
  • Table 6: Global Endonucleases Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 7: Global Endonucleases Market Revenue (USD million) Forecast, by Region, 2019-2032
  • Table 8: North America Endonucleases Market Revenue (USD million) Forecast, by Type, 2019-2032
  • Table 9: North America Endonucleases Market Revenue (USD million) Forecast, by Specific Endonucleases, 2019-2032
  • Table 10: North America Endonucleases Market Revenue (USD million) Forecast, by Non-specific Endonucleases, 2019-2032
  • Table 11: North America Endonucleases Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 12: North America Endonucleases Market Revenue (USD million) Forecast, by Source, 2019-2032
  • Table 13: North America Endonucleases Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 14: North America Endonucleases Market Revenue (USD million) Forecast, By Country, 2019-2032
  • Table 15: Europe Endonucleases Market Revenue (USD million) Forecast, by Type, 2019-2032
  • Table 16: Europe Endonucleases Market Revenue (USD million) Forecast, by Specific Endonucleases, 2019-2032
  • Table 17: Europe Endonucleases Market Revenue (USD million) Forecast, by Non-specific Endonucleases, 2019-2032
  • Table 18: Europe Endonucleases Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 19: Europe Endonucleases Market Revenue (USD million) Forecast, by Source, 2019-2032
  • Table 20: Europe Endonucleases Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 21: Europe Endonucleases Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 22: Asia Pacific Endonucleases Market Revenue (USD million) Forecast, by Type, 2019-2032
  • Table 23: Asia Pacific Endonucleases Market Revenue (USD million) Forecast, by Specific Endonucleases, 2019-2032
  • Table 24: Asia Pacific Endonucleases Market Revenue (USD million) Forecast, by Non-specific Endonucleases, 2019-2032
  • Table 25: Asia Pacific Endonucleases Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 26: Asia Pacific Endonucleases Market Revenue (USD million) Forecast, by Source, 2019-2032
  • Table 27: Asia Pacific Endonucleases Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 28: Asia Pacific Endonucleases Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 29: Latin America Endonucleases Market Revenue (USD million) Forecast, by Type, 2019-2032
  • Table 30: Latin America Endonucleases Market Revenue (USD million) Forecast, by Specific Endonucleases, 2019-2032
  • Table 31: Latin America Endonucleases Market Revenue (USD million) Forecast, by Non-specific Endonucleases, 2019-2032
  • Table 32: Latin America Endonucleases Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 33: Latin America Endonucleases Market Revenue (USD million) Forecast, by Source, 2019-2032
  • Table 34: Latin America Endonucleases Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 35: Latin America Endonucleases Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 36: Middle East & Africa Endonucleases Market Revenue (USD million) Forecast, by Type, 2019-2032
  • Table 37: Middle East & Africa Endonucleases Market Revenue (USD million) Forecast, by Specific Endonucleases, 2019-2032
  • Table 38: Middle East & Africa Endonucleases Market Revenue (USD million) Forecast, by Non-specific Endonucleases, 2019-2032
  • Table 39: Middle East & Africa Endonucleases Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 40: Middle East & Africa Endonucleases Market Revenue (USD million) Forecast, by Source, 2019-2032
  • Table 41: Middle East & Africa Endonucleases Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 42: Middle East & Africa Endonucleases Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Endonucleases Market Revenue Breakdown (USD million, %) by Region, 2024 & 2032
  • Figure 2: Global Endonucleases Market Value Share (%), by Type, 2024 & 2032
  • Figure 3: Global Endonucleases Market Value Share (%), by Application, 2024 & 2032
  • Figure 4: Global Endonucleases Market Value Share (%), by Source, 2024 & 2032
  • Figure 5: Global Endonucleases Market Value Share (%), by End User, 2024 & 2032
  • Figure 6: Global Endonucleases Market Value (USD million), by Region, 2024 & 2032
  • Figure 7: North America Endonucleases Market Value (USD million), by Type, 2024 & 2032
  • Figure 8: North America Endonucleases Market Value Share (%), by Type, 2024
  • Figure 9: North America Endonucleases Market Value (USD million), by Application, 2024 & 2032
  • Figure 10: North America Endonucleases Market Value Share (%), by Application, 2024
  • Figure 11: North America Endonucleases Market Value (USD million), by Source, 2024 & 2032
  • Figure 12: North America Endonucleases Market Value Share (%), by Source, 2024
  • Figure 13: North America Endonucleases Market Value (USD million), by End User, 2024 & 2032
  • Figure 14: North America Endonucleases Market Value Share (%), by End User, 2024
  • Figure 15: North America Endonucleases Market Value (USD million), By Country, 2024 & 2032
  • Figure 16: North America Endonucleases Market Value Share (%), By Country, 2024
  • Figure 17: Europe Endonucleases Market Value (USD million), by Type, 2024 & 2032
  • Figure 18: Europe Endonucleases Market Value Share (%), by Type, 2024
  • Figure 19: Europe Endonucleases Market Value (USD million), by Application, 2024 & 2032
  • Figure 20: Europe Endonucleases Market Value Share (%), by Application, 2024
  • Figure 21: Europe Endonucleases Market Value (USD million), by Source, 2024 & 2032
  • Figure 22: Europe Endonucleases Market Value Share (%), by Source, 2024
  • Figure 23: Europe Endonucleases Market Value (USD million), by End User, 2024 & 2032
  • Figure 24: Europe Endonucleases Market Value Share (%), by End User, 2024
  • Figure 25: Europe Endonucleases Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 26: Europe Endonucleases Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 27: Asia Pacific Endonucleases Market Value (USD million), by Type, 2024 & 2032
  • Figure 28: Asia Pacific Endonucleases Market Value Share (%), by Type, 2024
  • Figure 29: Asia Pacific Endonucleases Market Value (USD million), by Application, 2024 & 2032
  • Figure 30: Asia Pacific Endonucleases Market Value Share (%), by Application, 2024
  • Figure 31: Asia Pacific Endonucleases Market Value (USD million), by Source, 2024 & 2032
  • Figure 32: Asia Pacific Endonucleases Market Value Share (%), by Source, 2024
  • Figure 33: Asia Pacific Endonucleases Market Value (USD million), by End User, 2024 & 2032
  • Figure 34: Asia Pacific Endonucleases Market Value Share (%), by End User, 2024
  • Figure 35: Asia Pacific Endonucleases Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 36: Asia Pacific Endonucleases Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 37: Latin America Endonucleases Market Value (USD million), by Type, 2024 & 2032
  • Figure 38: Latin America Endonucleases Market Value Share (%), by Type, 2024
  • Figure 39: Latin America Endonucleases Market Value (USD million), by Application, 2024 & 2032
  • Figure 40: Latin America Endonucleases Market Value Share (%), by Application, 2024
  • Figure 41: Latin America Endonucleases Market Value (USD million), by Source, 2024 & 2032
  • Figure 42: Latin America Endonucleases Market Value Share (%), by Source, 2024
  • Figure 43: Latin America Endonucleases Market Value (USD million), by End User, 2024 & 2032
  • Figure 44: Latin America Endonucleases Market Value Share (%), by End User, 2024
  • Figure 45: Latin America Endonucleases Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 46: Latin America Endonucleases Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 47: Middle East & Africa Endonucleases Market Value (USD million), by Type, 2024 & 2032
  • Figure 48: Middle East & Africa Endonucleases Market Value Share (%), by Type, 2024
  • Figure 49: Middle East & Africa Endonucleases Market Value (USD million), by Application, 2024 & 2032
  • Figure 50: Middle East & Africa Endonucleases Market Value Share (%), by Application, 2024
  • Figure 51: Middle East & Africa Endonucleases Market Value (USD million), by Source, 2024 & 2032
  • Figure 52: Middle East & Africa Endonucleases Market Value Share (%), by Source, 2024
  • Figure 53: Middle East & Africa Endonucleases Market Value (USD million), by End User, 2024 & 2032
  • Figure 54: Middle East & Africa Endonucleases Market Value Share (%), by End User, 2024
  • Figure 55: Middle East & Africa Endonucleases Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 56: Middle East & Africa Endonucleases Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 57: Global Endonucleases Market Share (%), By Company, 2024